Best Growth Stocks to Buy for September 17th

Zacks highlighted Petco, Arrow Electronics and Oscar Health as Zacks Rank #1 stocks, citing upward revisions to current-year earnings estimates. Consensus EPS estimates increased 26.3% for Petco, 10.9% for Arrow Electronics and 161% for Oscar Health over the past 60 days. The article is analyst-driven stock-selection commentary and is unlikely to have broad market impact.

Analysis

This is low-information sell-side screen output, not a fundamental catalyst; estimate revisions alone are especially vulnerable to stale guidance, model normalization, and short-covering. The highest-risk interpretation is to extrapolate percentage revision magnitude without checking the absolute earnings base, forward multiple, and whether revisions reflect operating improvement versus one-time items. No broad read-through is warranted for AMZN, GOOG, or NVDA from promotional AI language.

WOOF is the most fragile of the three: a retailer with meaningful fixed-cost and discretionary-category exposure needs transaction growth and gross-margin durability, not merely higher EPS estimates. Its competitive set—CHWY, WMT, TGT, and AMZN—can trade margin for share, so any apparent earnings recovery could be capped by promotional intensity over the next 1-3 months. A durable rerating requires evidence that services/consumables mix and retention offset price competition.

ARW's revisions can be a late-cycle signal if they reflect inventory normalization rather than end-demand acceleration. The key second-order question is whether industrial and embedded-component bookings are improving faster than peers AVT and TTI/BRK; distributor earnings can inflect sharply on working-capital release, but that is lower quality than a sustained book-to-bill recovery. OSCR has the clearest operating leverage, but its valuation remains highly exposed to medical-cost trends and ACA-policy headlines; a favorable earnings revision does not de-risk utilization or risk-adjustment execution over the next 6-18 months.

Contrarian view: the market often chases large revision percentages in smaller, high-beta names after the move has occurred. Treat these as watch-list prompts until revisions are corroborated by guidance, quarterly KPIs, and relative-price strength versus sector peers; the article's low expected impact argues against initiating positions solely on this signal.

Key Decisions for Investors

• No immediate directional trade based solely on this screen. Require independently verified next-quarter guidance or KPI confirmation before deploying capital; reassess after each issuer's next earnings release.
• WOOF: maintain a cautious relative-value bias, long CHWY versus short WOOF only if WOOF underperforms on comparable-sales or gross-margin guidance while CHWY sustains active-customer and Autoship growth. Use a 1-3 month horizon; exit if WOOF demonstrates two consecutive quarters of positive comp growth with expanding EBITDA margin.
• ARW: place an alert for improving book-to-bill and inventory days versus AVT. If both validate a genuine demand upcycle, favor long ARW / short AVT for 3-6 months; do not enter if earnings upside is driven principally by inventory liquidation or lower operating expenses.
• OSCR: monitor medical-loss-ratio guidance, membership growth, and risk-adjustment commentary at the next results. Consider a defined-risk long only after MLR guidance is maintained or raised constructively; thesis is falsified by an MLR deterioration, adverse ACA-policy development, or membership growth that requires materially higher acquisition spend.